Surgical Robotics

Remote and Autonomous Surgical Robots in 2027: 8 Questions Before Anyone Operates From Another Building

Dr. Sarah Matt, MD, MBA  |  November 17, 2026  |  5 min read

No fully autonomous or remotely teleoperated surgical robot is cleared for use in the United States. As of July 2026, FDA says, none has been granted marketing authorization. On November 6 the agency published a discussion paper asking how it should weigh benefit and risk when one arrives, and the public docket stays open until January 5, 2027.

For a hospital, the useful work starts before any application lands. Most of it has nothing to do with the robot.

What FDA actually published

The paper is titled "Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities." FDA states plainly that this is not draft or final guidance. What it contains is fifteen numbered questions, and the agency wants answers.

Partial autonomy is not new. FDA notes that robotic systems with autonomous capabilities have been on the U.S. market for years. The new territory is full autonomy and an operator who is not in the building.

It is closer than it sounds. MedTech Dive reported that in October a surgeon performed a robotic prostatectomy from about 35 miles away under an investigational device exemption.

The room when the link drops

Every robotic case I have seen has a person at the bedside who matters more than the console. They dock the arms. They swap instruments. When something goes wrong, they are the first pair of hands on the patient.

In a remote case that person is the whole contingency plan.

The paper's questions circle that moment without naming it. Question 6 asks about automation bias and delays in override and control transition. A later question asks how teams manage emergencies and convert to a manual procedure. Another asks what happens as the on-site clinician shifts from doing the operation to watching it.

A surgeon three states away can be brilliant. If the line goes quiet for four seconds with a vessel half-divided, the outcome belongs to whoever is scrubbed at the table, and to whether anyone ever rehearsed it.

8 questions for the committee that will credential this

  1. Who is the surgeon of record, and where are they licensed? A remote surgeon in another state is practicing medicine in yours. Credentialing, privileging and licensure have to line up before the first case, not after.
  2. Who is scrubbed at the bedside, and what are they privileged to do alone? If the answer is "a nurse and a tech," the conversion plan is a phone call.
  3. What latency has the vendor validated, and what does the system do above it? FDA gives no number. The vendor should have one, in writing, with the behavior that follows: pause, hold, or hand control to the bedside.
  4. What is the conversion plan, and when was it last drilled? Open, laparoscopic, or transfer. By whom. In how many minutes.
  5. Which steps run at which autonomy level? "Autonomous" means nothing until someone names the level for each step of the procedure.
  6. Who owns the network? Hospital IT, the vendor, or a telecom carrier. The contract has to say whose failure a dropped link is, and who is on call for it at 2 AM.
  7. How is an override recorded? Time, person, reason. An override with no reason in the record is invisible at the morbidity and mortality conference and indefensible afterward.
  8. What postmarket data comes back to you? Your own complication and conversion rates, not the vendor's aggregate.

How the risk changes with distance

Operator locationBedside backupLicensure questionNetwork exposure
Next room, same hospitalSurgeon can walk inNone newInternal network
Another hospital, same regionLocal team onlyUsually same stateHospital-to-hospital link
Another state or countryLocal team onlyInterstate or internationalCarrier and internet path

The further the console, the more the outcome rests on people the remote surgeon has never worked with.

What I would do before January 5

Read the paper. It is short and the questions are good.

Send FDA a number. If your surgeons and anesthesiologists have a view on the latency they would accept before they want a human hand on the instrument, the docket is where it counts. The agency asked and has no answer of its own yet.

Then run one tabletop drill with your robotics team: the console goes dark at minute 40. Who moves first?

If the console went dark at minute 40 tomorrow, who in your OR would move first, and have they ever practiced it?

Sources: FDA, "Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities," discussion paper, November 2026, docket FDA-2026-N-13135; AHA News, November 9, 2026; MedTech Dive, November 9, 2026.


Clinical AI Governance Assessment

Dr. Sarah Matt is a surgery-trained physician-executive currently practicing internal medicine (charity care). She advises health systems and digital health companies on clinical AI implementation, vendor contracting and operational strategy.


Book a scoping call
Read more articles

The Sarah Matt Briefing

Weekly clinical reality on AI, governance, and what actually works inside health systems.